|
Age at diagnosis, years, median [IQR]
|
63.2 [52.0;73.0]
|
|
Age at metastasis, years, median [IQR]
|
67.0 [55.0;75.0]
|
|
Male sex, n (%)
|
172 (63.2)
|
|
Basal LDH, n (%)
|
|
Normal
|
171 (62.87)
|
|
Increased
|
79 (29)
|
|
Not available
|
22 (8.1)
|
|
Mutational status
|
|
BRAF/NRAS wild type
|
145 (53.3)
|
|
NRAS mutated
|
127 (46.7)
|
|
N of metastatic sites < 3, n (%)
|
169 (62.1)
|
|
Site of melanoma
|
|
Cutaneous
|
210 (77.2)
|
|
Mucosal
|
19 (7)
|
|
Ocular
|
14 (5.1)
|
|
Unknown
|
29 (10.7)
|
|
Prior adjuvant therapy
|
20 (7.3%)
|
|
ECOG PS
|
|
0
|
192 (70.6)
|
|
1
|
78 (28.7)
|
|
2
|
2 (0.7)
|
|
Stage at metastatic disease (AJCC VIII edition)
|
|
M1a
|
66 (24.3)
|
|
M1b
|
77 (28.3)
|
|
M1c
|
102 (37.5)
|
|
M1d
|
27 (9.9)
|
|
First line therapy
|
|
Anti-PD-1
|
209 (76.8)
|
|
Anti-CTLA-4
|
57 (20.9)
|
|
Anti-PD-1 + Anti-CTLA-4
|
6 (2.2)
|
